Adis Journals
Browse
Summary Slide.png (104.3 kB)

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Download (104.3 kB)
media
posted on 2021-02-05, 14:32 authored by Haleh Chehrehgosha, Masoud Reza Sohrabi, Faramarz Ismail-Beigi, Mojtaba Malek, Mohammad Reza babaei, Farhad Zamani, Hossein Ajdarkosh, Mahmood Khoonsari, Afshin Eshghi Fallah, Mohammad E. Khamseh

Article full text


The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2021.

History

Usage metrics

    Diabetes Therapy

    Categories

    Keywords

    Body CompositionFibroscanLiver FibrosisNon-Alcoholic Fatty Liver Disease (NAFLD)EmpagliflozinPioglitazoneSteatosis

    Licence

    CC BY-NC 4.0

    Exports